المؤلفون: Christine PERCICOT, Dorit RAZ, George N. LAMBROU, Phillip H. KASS, Ron OFRI

المصدر: Journal of Veterinary Medical Science. 2000, 62(12):1313

المؤلفون: Ron Ofri, Phillip H. Kass, Dorit Raz, George N. Lambrou, Christine L. Percicot

المصدر: Journal of Veterinary Medical Science. 62:1313-1315

مصطلحات موضوعية: Applanation tonometry, medicine.medical_specialty, Intraocular pressure, genetic structures, Glaucoma, Dinoprost, Placebo, Random Allocation, Tonometry, Ocular, Unoprostone Isopropyl, Dogs, Ophthalmology, medicine, Animals, Dog Diseases, Intraocular Pressure, General Veterinary, business.industry, Fatty Acids, Pupil size, medicine.disease, eye diseases, Canine glaucoma, Anesthesia, sense organs, Ophthalmic Solutions, business, After treatment

الوصف: Rescula (0.12% unoprostone isopropyl) is the first docosanoid compound approved for treatment of glaucoma in humans. It is commercially available in Japan, and is undergoing clinical testing elsewhere. The aim of this study was to evaluate the effect of Rescula on intraocular pressure (IOP) in normotensive dogs. After establishing a baseline diurnal IOP curve, six dogs were unilaterally treated with Rescula while the contralateral eye was treated with a placebo. Applanation tonometry was performed in both eyes, and pupil size was evaluated, 30 min after treatment, and at 1-hr intervals for the next 9 hr. Rescula caused a significant (p=0.014) and long-lasting decrease in IOP, from 20.49+/-2.02 mm Hg in control eyes to 15.49+/-0.69 mm Hg in treated eyes. These results suggest that Rescula is potentially efficacious in treatment of canine glaucoma.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deba66e10c0f6ff85c91cc01b8e1a42bTest
https://doi.org/10.1292/jvms.62.1313Test